Safety switches are described as incorporated elements that precisely control CAR-T cell activation. They are presented as a core strategy for improving safety in cellular immunotherapies.
First-pass extracted concept
safety switches
Candidate: concept label2 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
Evidence Snippets
future directions for integrating Boolean logic circuits, safety switches, and automated GMP-compliant processes
In this review, we summarize the main approaches that have been developed to face such bottlenecks, including... the incorporation of safety switches to precisely control CAR-T cell activation.
Supporting Sources
Linked Claims
Future directions include integrating Boolean logic circuits, safety switches, and automated GMP-compliant processes.
The review summarizes adapter CAR systems, Boolean-logic gating, epitope editing, modulation of cell-intrinsic signaling pathways, safety switches, and co-stimulatory domain selection as main approaches to address CAR-T bottlenecks.
Safety switches are incorporated to precisely control CAR-T cell activation.
Antigen escape variants, off-tumor destruction of healthy tissues expressing tumor-associated antigens, poor CAR-T cell persistence, and functional exhaustion are prominent hurdles limiting long-lasting remissions with tolerable adverse effects.
CAR-engineered T-cell therapy has achieved unprecedented response rates in some hematological malignancies but remains far from fulfilling its potential, especially in solid cancers.